The inhalation formulation is expected to deliver treatment directly to the lungs, reducing the potential for systemic toxicity. The Food and Drug Administration (FDA) has granted Fast Track ...
A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease has been discontinued. The ...
There are worries that people with cystic fibrosis (CF) and nontuberculous mycobacteria (NTM) might not live as long after transplant as those with CF without NTM, but we found no clear evidence about ...
MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the world prepares to observe World NTM Day on August 4, 2025, NTM Info & Research (NTMir) is calling on patients, physicians, caregivers, and policy leaders to ...
For most Americans, the letters "NTM" don’t mean anything. But for tens of thousands of people across the country, they represent something serious: a chronic lung disease that’s often overlooked, ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of innovative inhaled ...
Please provide your email address to receive an email when new articles are posted on . The ICoN-1 trial has been discontinued, and futility was the reason for this decision. The company is still ...
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause ...
Miami (July 31, 2025) – The Bronchiectasis and NTM Association joins other global patient advocacy organizations, professional societies, and lung health experts for the third annual World NTM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results